Alan Nurden: Safer Antithrombotic Therapy Through GPVI
Alan Nurden, Emeritus Research Director at CNRS, Co-Founder of the French National Reference Centre for Inherited Platelet Disorders (CRPP), shared a post on LinkedIn about a recent article by Stefano Navarro et al. published in Signal Transduction and Targeted Therapy, adding:
“Targeting GPVI in anti-thrombotic therapy
The absence of significant bleeding in patients deficient in the platelet collagen receptor GPVI makes this receptor an attractive target for anti-thrombotic therapy.
Results from several mouse models also point in this direction.
However, initial results from studies on the use of antibody-based therapies have been mixed and disappointing.
Now, in this article from the group led by Bernhard Nieswandt in the University of Wuerzburg, the authors present a carefully thought-out evaluation of the ways that GPVI can be targeted in clinic.
Using different mouse models, they show that monoclonal antibody-induced stripping of GPVI from the platelet surface in the liver sinusoids provides a more effective and longer inhibition than the short-term blocking of GPVI function by monoclonal antibody Fab fragments.
At the same time, hemostasis is maintained. Strikingly, they also show that pharmacologic downregulation of GPVI from platelets does not have to be complete to assure anti-thrombotic protection.
This re-opens the case for anti-GPVI therapy not only for ischemic stroke and arterial thrombosis but also in a wider perspective for thrombo-inflammation. This article is highly recommended and congratulations to the authors.”
Title: Partial downregulation of platelet glycoprotein VI by low affinity antibodies confers sustained and safe antithrombotic protection
Authors: Stefano Navarro, Sarah Beck, Sabrina I. Bonfiglio, Ernesto J. Cuenca-Zamora, Lukas J. Weiß, Marijke Kuijpers, Johan Heemskerk, David Stegner, Bernhard Nieswandt

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 20, 2026, 12:33Ney Carter Borges: The Evolving Role of Aspirin in Coronary Artery Disease
-
Jul 20, 2026, 12:15Zain Khalpey: Why the Cause of Reduced Perfusion Matters
-
Jul 20, 2026, 11:53ISTH 2026 Showcases Landmark Research and Launches Women’s Health Hub
-
Jul 20, 2026, 10:40Omid Seidizadeh: Advancing Genomic Insights into Bleeding Disorders at ISTH 2026
-
Jul 20, 2026, 10:30Marc Blondon: What Are the Current Practices For VTE Prevention in Pregnancy Worldwide?
-
Jul 20, 2026, 10:11Zeyad Bady: Advancing Thrombosis Research on the International Stage at ISTH 2026
-
Jul 20, 2026, 09:41Emily Bury: From Emerging Evidence to Better Patient Care at ISTH 2026
-
Jul 20, 2026, 08:58Samantha Pasca: Insights into Pain and Coping in Hemophilia at ISTH 2026
-
Jul 20, 2026, 08:08Ifeanyichukwu Ifechidere: COVID-19 Changed Our Understanding of Coagulation